Correction: Current outlook on radionuclide delivery systems: From design consideration to translation into clinics (Journal of Nanobiotechnology (2019) 17:1 (90) DOI: 10.1186/s12951-019-0524-9)

Oleksii O. Peltek, Albert R. Muslimov, Mikhail V. Zyuzin, Alexander S. Timin

Research output: Contribution to journalComment/debate

Abstract

After publication of this article, an error was found in the description of the holmium isotopes. 165Ho is a stable isotope a fraction of which is activated to 166Ho by neutron activation in a nuclear reactor [2]. In one paragraph of the published article, describing holmium containing QuiremSpheres, 165Ho should be replaced with 166Ho. The correct description is given below. "QuiremSpheres are poly-l-lactic acid based microspheres, containing 166Ho. The size of the particles varies from 15 to 60 µm and the use of poly-l-lactic acid allows to achieve the particle density of 1.4 g/cm3, which is closer to the density of blood (1.06 g/cm3). The 165Ho is activated to 166Ho with neutron activation in a nuclear reactor. Due to the short half-life period of 166Ho, each patient dose of QuiremSpheres needs to be prepared separately, thus, a specific activity can differ in each dose and depends on the needs of a patient".

Original languageEnglish
Article number2
JournalJournal of Nanobiotechnology
Volume18
Issue number1
DOIs
Publication statusPublished - 2 Jan 2020

Fingerprint

Holmium
Nanobiotechnology
Nuclear Reactors
Neutrons
Lactic acid
Nuclear reactors
Radioisotopes
Isotopes
Lactic Acid
Chemical activation
Microspheres
Particle Size
Half-Life
Publications
Blood
poly(lactic acid)

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Applied Microbiology and Biotechnology
  • Pharmaceutical Science

Cite this

@article{3e5deeb8ba8146c6adbbf1fd3ff3d8f7,
title = "Correction: Current outlook on radionuclide delivery systems: From design consideration to translation into clinics (Journal of Nanobiotechnology (2019) 17:1 (90) DOI: 10.1186/s12951-019-0524-9)",
abstract = "After publication of this article, an error was found in the description of the holmium isotopes. 165Ho is a stable isotope a fraction of which is activated to 166Ho by neutron activation in a nuclear reactor [2]. In one paragraph of the published article, describing holmium containing QuiremSpheres, 165Ho should be replaced with 166Ho. The correct description is given below. {"}QuiremSpheres are poly-l-lactic acid based microspheres, containing 166Ho. The size of the particles varies from 15 to 60 µm and the use of poly-l-lactic acid allows to achieve the particle density of 1.4 g/cm3, which is closer to the density of blood (1.06 g/cm3). The 165Ho is activated to 166Ho with neutron activation in a nuclear reactor. Due to the short half-life period of 166Ho, each patient dose of QuiremSpheres needs to be prepared separately, thus, a specific activity can differ in each dose and depends on the needs of a patient{"}.",
author = "Peltek, {Oleksii O.} and Muslimov, {Albert R.} and Zyuzin, {Mikhail V.} and Timin, {Alexander S.}",
year = "2020",
month = "1",
day = "2",
doi = "10.1186/s12951-019-0558-z",
language = "English",
volume = "18",
journal = "Journal of Nanobiotechnology",
issn = "1477-3155",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Correction

T2 - Current outlook on radionuclide delivery systems: From design consideration to translation into clinics (Journal of Nanobiotechnology (2019) 17:1 (90) DOI: 10.1186/s12951-019-0524-9)

AU - Peltek, Oleksii O.

AU - Muslimov, Albert R.

AU - Zyuzin, Mikhail V.

AU - Timin, Alexander S.

PY - 2020/1/2

Y1 - 2020/1/2

N2 - After publication of this article, an error was found in the description of the holmium isotopes. 165Ho is a stable isotope a fraction of which is activated to 166Ho by neutron activation in a nuclear reactor [2]. In one paragraph of the published article, describing holmium containing QuiremSpheres, 165Ho should be replaced with 166Ho. The correct description is given below. "QuiremSpheres are poly-l-lactic acid based microspheres, containing 166Ho. The size of the particles varies from 15 to 60 µm and the use of poly-l-lactic acid allows to achieve the particle density of 1.4 g/cm3, which is closer to the density of blood (1.06 g/cm3). The 165Ho is activated to 166Ho with neutron activation in a nuclear reactor. Due to the short half-life period of 166Ho, each patient dose of QuiremSpheres needs to be prepared separately, thus, a specific activity can differ in each dose and depends on the needs of a patient".

AB - After publication of this article, an error was found in the description of the holmium isotopes. 165Ho is a stable isotope a fraction of which is activated to 166Ho by neutron activation in a nuclear reactor [2]. In one paragraph of the published article, describing holmium containing QuiremSpheres, 165Ho should be replaced with 166Ho. The correct description is given below. "QuiremSpheres are poly-l-lactic acid based microspheres, containing 166Ho. The size of the particles varies from 15 to 60 µm and the use of poly-l-lactic acid allows to achieve the particle density of 1.4 g/cm3, which is closer to the density of blood (1.06 g/cm3). The 165Ho is activated to 166Ho with neutron activation in a nuclear reactor. Due to the short half-life period of 166Ho, each patient dose of QuiremSpheres needs to be prepared separately, thus, a specific activity can differ in each dose and depends on the needs of a patient".

UR - http://www.scopus.com/inward/record.url?scp=85077472964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077472964&partnerID=8YFLogxK

U2 - 10.1186/s12951-019-0558-z

DO - 10.1186/s12951-019-0558-z

M3 - Comment/debate

C2 - 31898505

AN - SCOPUS:85077472964

VL - 18

JO - Journal of Nanobiotechnology

JF - Journal of Nanobiotechnology

SN - 1477-3155

IS - 1

M1 - 2

ER -